Company news

Janux Therapeutics, Inc. news in 2024

Janux Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

December 5, 2024

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

December 3, 2024

Janux Therapeutics Announces Proposed Public Offering

December 2, 2024

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

December 1, 2024

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

November 24, 2024

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

November 5, 2024

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

August 6, 2024

Janux Therapeutics Announces Updates to Board of Directors

July 21, 2024

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 6, 2024

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

March 7, 2024

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

February 28, 2024

Janux Therapeutics Announces Proposed Public Offering of Common Stock

February 26, 2024

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

February 25, 2024

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

February 19, 2024

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

January 7, 2024

Decks in 2024